KEPLER

  • What's involved: A Phase 3b, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety OVX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del
  • Take part: Open
  • Principal Investigator: Dr Helen Barr
Research Theme | Respiratory | Mental Health & Technology

What's involved

A Phase 3b, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety OVX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del

Principal Investigator

Dr Helen Barr

Take part

Open
Back to all trials

Contact Us

NIHR Biomedical Research Centre: Nottingham
Research & Innovation
D Floor (via South Block)
Nottingham University Hospitals NHS Trust
Queen’s Medical Centre
Derby Road
Nottingham
NG7 2UH

Telephone: 0115 924 9924

Director: Professor Ian Hall

Hosted by

Nottingham University Hospitals Logo

Nottingham University Hospitals Logo

We are a partnership between Nottingham University Hospitals NHS Trust and the University of Nottingham, supported by NHS and academic partners in Nottingham and across the East Midlands.

Website by Volute